Biotechnology company Renovis Inc. said Tuesday it filed a universal shelf registration statement with the Securities and Exchange Commission to sell up to $150 million of its stock, securities and warrants.
The company does not have any current plans for an offering and will establish any terms when they make an offer.
Perform A Background Check On Anyone, Anywhere In The World
The SEC must approve the filing before Renovis can offer stock.
Renovis discovers and develops drugs that treat neurological and inflammatory diseases. Shares closed Monday at $13.59 on the Nasdaq.
The company does not have any current plans for an offering and will establish any terms when they make an offer.
Perform A Background Check On Anyone, Anywhere In The World
The SEC must approve the filing before Renovis can offer stock.
Renovis discovers and develops drugs that treat neurological and inflammatory diseases. Shares closed Monday at $13.59 on the Nasdaq.
posted by doublezero at
11:13 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home